<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785029</url>
  </required_header>
  <id_info>
    <org_study_id>S-2015-1-aa</org_study_id>
    <nct_id>NCT02785029</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1)</brief_title>
  <official_title>Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg Engineering GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg Engineering GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single-arm clinical multicenter study intends to measure normal structural&#xD;
      parameters of the optic nerve head, the peripapillary retinal nerve fiber layer, and the&#xD;
      macula using the Heidelberg Spectralis OCT device. This study is conducted in&#xD;
      African-American descent volunteers. The main goal of the study is to provide the range of&#xD;
      these structural parameters in normal eyes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, single-arm clinical multicenter study intends to measure normal structural&#xD;
      parameters of the optic nerve head, the peripapillary retinal nerve fiber layer, and the&#xD;
      macula using the Heidelberg Spectralis OCT device. This study is conducted in&#xD;
      African-American descent volunteers. The main goal of the study is to provide the range of&#xD;
      these structural parameters in normal eyes. The study will include at least 240 normal&#xD;
      volunteers; up to 10 study sites will recruit subjects. Overall an approximately equal age&#xD;
      distribution from 18 to 90 years and an approximately equal number of females and males will&#xD;
      be enrolled (approximately 40-60% females in each age group). All subjects will undergo&#xD;
      Spectralis OCT imaging, biometric and ophthalmoscopic examination, disc photography and&#xD;
      visual field testing in one single visit, if possible. Repeated perimetry or Spectralis scans&#xD;
      may be performed at a second visit within 30 days of the initial visit. All examinations&#xD;
      performed on the subjects are non-significant risk procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bruch-Membrane-Opening - Minimum Rim Width (µm)</measure>
    <time_frame>Baseline</time_frame>
    <description>Bruch-Membrane-Opening - Minimum Rim Width (µm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bruch-Membrane-Opening - Minimum Rim Area (µm^2)</measure>
    <time_frame>Baseline</time_frame>
    <description>Bruch-Membrane-Opening - Minimum Rim Area (µm^2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer Thickness (µm)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripapillary Retinal Nerve Fibre Layer Thickness (µm)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">249</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Normal healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCT imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT</intervention_name>
    <arm_group_label>Normal healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to undergo the test procedures, give consent, and to follow&#xD;
             instructions.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age ≥18 to 90.&#xD;
&#xD;
          -  Healthy eye without prior intraocular surgery (except cataract surgery and Laser in&#xD;
             Situ Keratomileusis) and without clinically significant vitreal, retinal or choroidal&#xD;
             diseases, clinically significant diabetic retinopathy (subject may have diabetes), or&#xD;
             disease of the optic nerve. Small drusen are acceptable in older subjects.&#xD;
&#xD;
          -  Black or African-American decent (self-reported)&#xD;
&#xD;
          -  Negative history of glaucoma (not including family history)&#xD;
&#xD;
          -  Intraocular pressure ≤21mmHg.&#xD;
&#xD;
          -  Best corrected visual acuity ≥20/40.&#xD;
&#xD;
          -  Refraction between +6 and -6 diopters and astigmatism ≤ 2 diopters.&#xD;
&#xD;
          -  Axial length ≤ 26.0 mm (by optical biometry)&#xD;
&#xD;
          -  Normal visual field with Glaucoma Hemifield Test and Mean Deviation within normal&#xD;
             limits or not abnormal visual field by judgment of the ophthalmologist / optometrist&#xD;
&#xD;
          -  Clinically normal appearance of the optic disc, with normal appearing neuroretinal rim&#xD;
             with respect to color and shape. The optic disc is examined ophthalmoscopically and by&#xD;
             evaluation of stereo photographs.&#xD;
&#xD;
          -  If both eyes are eligible, both eyes enter the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vulnerable subjects (as defined in ISO 14155 GCP) with the exception of employees of&#xD;
             the site, and, if applicable, students of the respective university. Staff that is&#xD;
             listed on the delegation form are excluded from participation.&#xD;
&#xD;
          -  Subjects unable to read or write&#xD;
&#xD;
          -  Unreliable visual field. The reliability indices should be used as guide as well as&#xD;
             the perimetrist's notes.&#xD;
&#xD;
          -  Unusable disc stereo photos.&#xD;
&#xD;
          -  Inability to undergo the tests.&#xD;
&#xD;
          -  Insufficient quality of Spectralis OCT images (this is not determined until after&#xD;
             Spectralis OCT examination, and is an unusual circumstance).&#xD;
&#xD;
        Minimum requirements are:&#xD;
&#xD;
          -  Retina completely included in image frame,&#xD;
&#xD;
          -  Quality Score ≥ 20 in the stored ART mean images, and&#xD;
&#xD;
          -  For ONH-R scan: Center position error ≤ 100 μm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Balwantray Chauhan, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology and Visual Sciences Dalhousie University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Schulz, PhD</last_name>
    <phone>+49 6221 64630</phone>
    <email>thomas.schulz@heidelbergengineering.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Zangwill, MD</last_name>
    </contact>
    <investigator>
      <last_name>Linda Zangwill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assil Eye Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mid Florida Eye Center Clinic</name>
      <address>
        <city>Mount Dora</city>
        <state>Florida</state>
        <zip>32757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Illinois Eye Institute, Illinois College of Optometry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St Albans Community Living, Center, Queens Campus</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SUNY College of Optometry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island-Valley Stream</name>
      <address>
        <city>Valley Stream</city>
        <state>New York</state>
        <zip>11581</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

